Jacqueline Sutter, DO
Pulmonary Disease · Wynnewood, PANPI 1417113325
Payments from drug & device makers
Across 537 payments — averaging $403.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$72K
- Boehringer Ingelheim$50K
- Sanofi$32K
- AstraZeneca$28K
- Regeneron$27K
- ANI Pharmaceuticals, Inc.$1K
- plus $6K from 32 others
What the payments were for
- Consulting fees$23,54712%
- Speaking & faculty fees$133,95471%
- Travel & lodging$17,2239%
- Food & beverage$13,9737%
- Education$1560%
- Gifts$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 111 | $71,821 |
| Boehringer Ingelheim | 99 | $50,398 |
| Sanofi | 46 | $31,692 |
| AstraZeneca(2 entities) | 110 | $27,849 |
| Regeneron | 3 | $27,450 |
| ANI Pharmaceuticals, Inc. | 10 | $1,478 |
| Intuitive Surgical | 20 | $1,321 |
| GSK | 47 | $915 |
| Johnson & Johnson | 4 | $847 |
| Bayer | 4 | $371 |
| Mylan Specialty L.p. | 10 | $304 |
| Galvanize Therapeutics, Inc | 2 | $237 |
| Genentech USA, Inc. | 10 | $203 |
| Insmed, Inc. | 5 | $171 |
| Verona Pharma, Inc. | 6 | $164 |
| AbbVie(2 entities) | 7 | $161 |
| Philips North America LLC | 6 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Pulmonx Corporation | 2 | $81 |
| Mallinckrodt Hospital Products Inc. | 3 | $76 |
| Covis Pharma GmbH | 3 | $73 |
| Novartis | 3 | $64 |
| Electromed, Inc. | 2 | $59 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Amgen | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Circassia Inc. | 2 | $32 |
| Inogen, Inc. | 1 | $28 |
| United Therapeutics Corporation | 1 | $26 |
| Viatris Specialty LLC | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Kaleo, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$111,790
- OFEV$26,760
- AIRSUPRA$20,289
- TAGRISSO$5,118
- PURIFIED CORTROPHIN GEL$1,275
- Da Vinci Surgical System$977
- MONARCH$817
- Adempas$325
- BREZTRI$237
- ALIYA SYSTEM$237
- FASENRA$126
- Yupelri$123
- NUCALA$102
How this compares
$216,439 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 362 | $263,769 |
| Dupixent PenDupilumab | 24 | $87,634 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 78 | $59,697 |
| Dupixent SyringeDupilumab | 12 | $52,463 |
| Spiriva RespimatTiotropium Bromide | 38 | $27,415 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $19,232 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $16,774 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $14,992 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $9,325 |
| Arnuity ElliptaFluticasone Furoate | 27 | $5,668 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $4,570 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $3,259 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,535 |
| Azithromycin | 78 | $615 |
| Prednisone | 128 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $915 | $310,528476 claims |
| AstraZenecaBreztri Aerosphere | $27,849 | $59,69778 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $50,398 | $46,64768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Wynnewood
- Thomas MeyerWynnewood$615K
- Eliot FriedmanWynnewood$254K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.